Introduction to Market Access for Pharmaceuticals

Häftad, Engelska, 2017

Av Mondher Toumi, France) Toumi, Mondher (Universite Claude Bernard Lyon-1

2 189 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.Key Features:The first guide to market access for pharmaceuticals based on tested teaching materialsAddresses both pharmaceutical and vaccine productsIncludes case studies and scenariosCovers market access consdierations for Western Europe, the USA, Japan and ChinaExplains the impact the changing healthcare market will have on your product

Produktinformation

Utgivningsdatum2017-01-04
Mått210 x 280 x 16 mm
Vikt486 g
FormatHäftad
SpråkEngelska
Antal sidor204
FörlagTaylor & Francis Ltd
ISBN9781138032187

Tillhör följande kategorier

Apotek och farmaceuter inom Medicin
Försäljning och marknadsföring inom Ekonomi och ledarskap
Tillverkningsindustri inom Ekonomi och ledarskap
Farmakologi inom Medicin

Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.

Chapter 1: Health as a GoodChapter 2: Decision-Making in Public HealthChapter 3: Definition and ConceptsChapter 4: HTA Decision Analysis frameworkChapter 5: Early HTA AdviceChapter 6: Overview of Market Access AgreementsChapter 7: External Reference PricingChapter 8: Gap between Payers and RegulatorsChapter 9: Early Access ProgramsChapter 10: Market Access of Orphan DrugsChapter 11: Market Access of Vaccines in Developed CountriesChapter 12: FranceChapter 13: GermanyChapter 14: ItalyChapter 15: SpainChapter 16: SwedenChapter 17: United KingdomChapter 18: The United StatesChapter 19: JapanChapter 20: China